Adagene Adds 13-Drug Approval Veteran Peter Lebowitz to Boost ADG126 Strategy
Adagene added industry veteran Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. His record of 13 drug approvals and 12 FDA Breakthrough Therapy designations at J&J will inform ADG126’s clinical development and strategies for registration-enabling studies in microsatellite-stable colorectal cancer.
1. Appointment Details
Adagene has appointed Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board to guide the clinical and regulatory advancement of its pipeline. Lebowitz will advise on development milestones, trial design and global regulatory interactions for ADG126 and other antibody-based therapies.
2. Lebowitz’s Industry Track Record
Lebowitz previously led Oncology R&D at Johnson & Johnson for 13 years, delivering 13 new drugs to market and securing 12 FDA Breakthrough Therapy designations. He currently serves as CEO of Third Arc Bio and has authored dozens of high-impact publications in oncology drug development.
3. Implications for ADG126
Lebowitz’s expertise in breakthrough therapy pathways and tumor-selective antibody modalities is expected to accelerate ADG126’s progression through Phase 2 studies. His guidance will focus on registration-enabling strategies for the masked anti-CTLA-4 SAFEbody in microsatellite-stable colorectal cancer, as well as combination approaches targeting intratumoral regulatory T cells.